Veracyte (NASDAQ:VCYT) Posts Earnings Results, Beats Estimates By $0.18 EPS

Veracyte (NASDAQ:VCYT) released its quarterly earnings data on Tuesday. The biotechnology company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.18, Briefing.com reports. The firm had revenue of $139.07 million for the quarter, compared to the consensus estimate of $130.36 million. Veracyte had a net margin of 16.25% and a return on equity of 9.22%. The firm’s revenue was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.31 earnings per share.

Here are the key takeaways from Veracyte’s conference call:

• Veracyte delivered a strong Q1 with $139.1M total revenue (up 21% YoY), testing revenue of $135.1M (+26%), adjusted EBITDA of $42.8M (30.8% margin), and raised 2026 revenue guidance to $582M–$592M with adjusted EBITDA >26%.
• The Decipher franchise remains the primary growth engine—~28,000 tests in Q1 (+24% YoY), ~30% growth in high?risk categories, and multiple Phase III studies (GUIDANCE, ENZAMET, PredictRT) and NCCN inclusion supporting longer?term uptake.
• Afirma volumes improved to ~17,200 tests (+12% YoY) after the full transition to the V2 transcriptome, which materially reduced no?result rates (adding ~400 bps to volume) and contributed to margin improvement.
• Two upcoming launches—Prosigna LDT (OPTIMA data at ASCO; commercial mid?year) and TruMRD in muscle?invasive bladder cancer (launch by end of Q2)—are positioned as major catalysts, but commercial impact is contingent on trial readouts, guideline/reimbursement decisions and adoption.
• Strong cash generation ($35.2M from operations; $439.1M cash/short?term investments) and improved gross margins (non?GAAP 75.7%) provide flexibility to fund R&D, commercial scale-up and selective M&A aligned with the company’s oncology focus.

Veracyte Trading Up 24.9%

Veracyte stock opened at $41.19 on Thursday. The stock has a 50-day moving average price of $33.44 and a 200 day moving average price of $38.20. Veracyte has a 52 week low of $22.61 and a 52 week high of $50.71. The stock has a market cap of $3.29 billion, a PE ratio of 37.79 and a beta of 1.89.

Insider Activity

In other Veracyte news, SVP Annie Mcguire sold 6,658 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $35.55, for a total value of $236,691.90. Following the completion of the transaction, the senior vice president directly owned 94,706 shares in the company, valued at approximately $3,366,798.30. The trade was a 6.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Rebecca Chambers sold 18,341 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $36.14, for a total value of $662,843.74. Following the sale, the chief financial officer owned 131,196 shares in the company, valued at $4,741,423.44. This trade represents a 12.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 75,782 shares of company stock valued at $2,722,097. 1.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of VCYT. California State Teachers Retirement System boosted its position in shares of Veracyte by 0.8% in the second quarter. California State Teachers Retirement System now owns 71,095 shares of the biotechnology company’s stock worth $1,922,000 after acquiring an additional 566 shares during the last quarter. O Shaughnessy Asset Management LLC boosted its holdings in shares of Veracyte by 7.9% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 7,894 shares of the biotechnology company’s stock valued at $332,000 after purchasing an additional 576 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Veracyte by 159.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,104 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 679 shares during the period. Xponance LLC raised its position in shares of Veracyte by 12.1% in the 4th quarter. Xponance LLC now owns 6,871 shares of the biotechnology company’s stock worth $289,000 after buying an additional 741 shares during the period. Finally, Osaic Holdings Inc. raised its position in shares of Veracyte by 21.0% in the 4th quarter. Osaic Holdings Inc. now owns 4,713 shares of the biotechnology company’s stock worth $198,000 after buying an additional 817 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group lifted their price target on shares of Veracyte from $40.00 to $42.00 and gave the company a “hold” rating in a research report on Wednesday. Zacks Research cut Veracyte from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 12th. Morgan Stanley lowered their target price on Veracyte from $48.00 to $37.00 and set an “underweight” rating on the stock in a report on Thursday, March 5th. Guggenheim cut their price target on Veracyte from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Finally, Jefferies Financial Group initiated coverage on shares of Veracyte in a research note on Monday, April 13th. They issued a “buy” rating and a $45.00 price objective on the stock. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $44.83.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.